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Summary
Background Delirium is frequently diagnosed in critically ill patients and is associated with poor clinical outcomes. 
Haloperidol is the most commonly used drug for delirium despite little evidence of its eﬀ ectiveness. The aim of this 
study was to establish whether early treatment with haloperidol would decrease the time that survivors of critical 
illness spent in delirium or coma.
Methods We did this double-blind, placebo-controlled randomised trial in a general adult intensive care unit (ICU). 
Critically ill patients (≥18 years) needing mechanical ventilation within 72 h of admission were enrolled. Patients were 
randomised (by an independent nurse, in 1:1 ratio, with permuted block size of four and six, using a centralised, secure 
web-based randomisation service) to receive haloperidol 2·5 mg or 0·9% saline placebo intravenously every 8 h, 
irrespective of coma or delirium status. Study drug was discontinued on ICU discharge, once delirium-free and coma-
free for 2 consecutive days, or after a maximum of 14 days of treatment, whichever came ﬁ rst. Delirium was assessed 
using the confusion assessment method for the ICU (CAM-ICU). The primary outcome was delirium-free and coma-
free days, deﬁ ned as the number of days in the ﬁ rst 14 days after randomisation during which the patient was alive 
without delirium and not in coma from any cause. Patients who died within the 14 day study period were recorded as 
having 0 days free of delirium and coma. ICU clinical and research staﬀ  and patients were masked to treatment 
throughout the study. Analyses were by intention to treat. This trial is registered with the International Standard 
Randomised Controlled Trial Registry, number ISRCTN83567338.
Findings 142 patients were randomised, 141 were included in the ﬁ nal analysis (71 haloperidol, 70 placebo). Patients in 
the haloperidol group spent about the same number of days alive, without delirium, and without coma as did patients in 
the placebo group (median 5 days [IQR 0–10] vs 6 days [0–11] days; p=0·53). The most common adverse events were 
oversedation (11 patients in the haloperidol group vs six in the placebo group) and QTc prolongation (seven patients in the 
haloperidol group vs six in the placebo group). No patient had a serious adverse event related to the study drug.
Interpretation These results do not support the hypothesis that haloperidol modiﬁ es duration of delirium in critically 
ill patients. Although haloperidol can be used safely in this population of patients, pending the results of trials in 
progress, the use of intravenous haloperidol should be reserved for short-term management of acute agitation.
Funding National Institute for Health Research.
Introduction
Delirium is a disorder characterised by acute brain 
dysfunction. Although causality between delirium and 
mortality is not established, critically ill patients who 
develop delirium are up to three times more likely to die 
by 6 months than are those who do not,1 with each 
additional day of delirium being associated with a 10% 
increase in the risk of death.2 Importantly, in mechanically 
ventilated patients delirium might be associated with 
long-term cognitive impairment.3 The incidence of 
delirium in patients in critical care is reported to be about 
30% overall,4 but is 60–80% in sedated ventilated patients, 
excluding those admitted after major elective surgery.1,5,6 
A point prevalence study of 497 patients in intensive care 
units (ICUs) in 11 countries showed that 68% of patients 
were either over sedated or shown to have delirium.7 
17 of 27 (63%) mechanically ventilated patients were 
shown to have delirium in a UK study.8
Delirium probably results from diverse patho-
physiological mechanisms, including derange ments of 
several neurotransmitter systems within the brain, but 
the underlying mechanisms are not fully understood. 
The most widely postulated theory is that delirium is 
caused by cholinergic deﬁ ciency with an excess of 
dopamine.9 The main mechanisms of action of 
haloperidol are thought to be antagonism at cortical 
dopamine (D2) receptors, nigrostriatal pathway D2 
blockade, and disinhibition of acetylcholine with 
acetylcholine increase.9 Haloperidol is extensively 
protein-bound and rapidly distributed throughout the 
body with a mean elimination half life of 21 h. The 
rationale for use of haloperidol also includes a reduction 
in the need for psychotropic sedative and analgesic drugs 
in ventilated patients, which have been shown to 
contribute to the risk of delirium,10 and potentially 
beneﬁ cial immunomodulatory eﬀ ects.11,12
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There is no reported evidence that treatment with 
haloperidol reduces incidence and duration of delirium in 
adult ICU patients.13 Despite this absence of evidence, 
haloperidol is commonly used in clinical practice to 
prevent and treat delirium in critically ill patients and has 
been used as part of routine sedation practice and as a 
quality improvement intervention.14,15 However, haloperidol 
is not innocuous because reports of harm associated with 
antipsychotic use in elderly patients are common.16,17
The aim of this trial was to test the hypothesis that in 
critically ill patients needing mechanical ventilation, 
early administration of intravenous haloperidol for the 
duration of the ICU stay or until delirium-free and coma-
free for 48 h would reduce the frequency and duration of 
delirium and improve other important clinical outcomes.
Methods
Study design and participants
We did a randomised, double-blind, placebo-controlled 
trial of intravenous haloperidol in adult (≥18 years) 
mechanically ventilated patients. Patients were recruited 
from the general mixed medical–surgical adult ICU in 
Watford General Hospital (Watford, UK). Patients were 
eligible for inclusion from the time they needed 
mechanical ventilation on the ICU, provided that was 
within 72 h of admission. Patients were excluded from 
the trial if they fulﬁ lled any of the following criteria: 
allergy to haloperidol as established by direct questioning 
of family members and available medical history, 
moderate to severe dementia as documented by medical 
history, Parkinson’s disease, structural brain damage, 
chronic antipsychotic use, corrected QTc interval (QTc) 
greater than 500 ms, history of torsades de pointes, 
history of neuroleptic malignant syndrome, family 
history of dystonic reactions to drugs, age younger than 
18 years, pregnancy, moribund and not expected to 
survive 48 h, or predicted ICU stay of less than 48 h. 
Patients who had undergone elective uncomplicated 
surgery, or who had been involved in a clinical trial of an 
investigational medicinal product in the previous 30 days 
were also excluded. Patients who had been enrolled into 
the study once were not enrolled again if they were 
readmitted to the ICU.
Sedated, mechanically ventilated patients did not have 
capacity to give consent; therefore, consistent with 
requirements of the European Union clinical trial 
directive, a member of the research team (VJP, TA, or 
XBZ) obtained written informed consent from a personal 
or professional legal representative before ran-
domisation. All surviving patients were informed about 
the trial at the earliest opportunity after regaining 
competence and then provided written consent to 
continue in the trial. The protocol was approved by the 
Berkshire Research Ethics Committee, the UK Medicines 
and Healthcare Products Regulatory Agency, and the 
Hertfordshire Hospitals Research and Development 
Consortium. The trial was coordinated by West 
Hertfordshire Hospitals National Health Service Trust in 
partnership with Warwick Clinical Trials Unit. An 
independent data monitoring and ethics committee 
monitored the trial for safety.
Randomisation and masking
A nurse from the operating theatre post-anaesthetic care 
unit (PACU), who was independent of the ICU clinical 
and research staﬀ , allocated patients in a 1 to 1 ratio, with 
random permuted blocks of size four and six, to 
haloperidol or placebo, using a centralised, secure web-
based randomisation service. Study drugs were prepared 
in the PACU, which is separate from the ICU, in identical 
2 mm syringes by an independent member of the PACU 
nursing staﬀ  who then directly administered the drug to 
study patients. All ICU clinical and research staﬀ , legal 
representatives, and the patients were masked to study 
drug. The data monitoring and safety committee 
reviewed blinded data reports. Statisticians were not 
masked to allocation. The success of masking was not 
formally assessed.
Figure 1: Trial proﬁ le
*20 patients had more than one reason for exclusion.
1 discontinued intervention (patient 
    withdrew consent for additional 
    follow-up: consented to use of 
    collected data)
677 assessed for eligibility
142 randomised
71 assigned to haloperidol 71 assigned to placebo
71 included in analysis 70 included in analysis
1 lost to follow-up (no consent to 
    continue gained: data destroyed)
1 discontinued intervention 
   (personal legal representative
   withdrew consent)
535 excluded*
         114 expected to be discharged within 48 h of admission
         107 declined to participate
           97 moribund, unlikely to survive more than 48 h
           49 undergone uncomplicated elective surgery
           37 more than 72 h from admission
           28 QTc more than 500 ms on current ECG
           28 already on antipsychotics
           24 moderate to severe dementia or cognitive 
                  impairment
           23 structural brain damage
           17 language diﬃculty: learning or English language 
                 disability
             7 Parkinson’s disease
             6 previously participated in Hope-ICU
             2 haloperidol allergy
             1 younger than 18 years
           15 others
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Procedures
Treatment was initiated within 72 h of admission to ICU, 
irrespective of coma or outcome of the confusion 
assessment method for the ICU (CAM-ICU).18 Patients 
received either haloperidol 2·5 mg or an equal volume 
(0·5 mL) of 0·9% saline placebo intravenously every 8 h, 
according to their group allocation. The ﬁ rst dose was 
given at either 8 am, 4 pm, or midnight, depending on the 
time of randomisation. The dosing regimen for this trial 
was based on existing clinical practice for management of 
delirium in critically ill patients by UK consultant 
intensivists, as established by the UK Intensive Care 
Foundation in 2008.19 Study drug was discontinued in all 
patients on ICU discharge, when the patient was 
delirium-free for two consecutive days, or after a 
maximum of 14 days treatment, whichever came ﬁ rst. 
Study drug was not tapered in view of the short course of 
treatment and because patients were often discharged 
once they were free of delirium. Study drug was restarted 
if the patient was subsequently assessed positive for 
delirium by CAM-ICU within the 14 day study period.
Patients were maintained using fentanyl and propofol 
sedative infusions titrated to a Richmond agitation 
sedation scale (RASS) target of 0 to –1,20 unless the 
consultant intensivist responsible for clinical 
management decided a deeper level of sedation was 
needed on a given day. RASS was assessed every 4 h. We 
did not use a formal pain score—analgesics were titrated 
according to the bedside nurse’s judgment of the patient’s 
level of comfort and pain. When a patient was 
oversedated—ie, one or more points deeper than target 
RASS after sedative infusions were stopped for more 
than 24 h—the dose of study drug was halved. When 
oversedation persisted for an additional 24 h, the study 
drug was stopped. Weaning from ventilation was 
according to a standard protocol and included 
spontaneous breathing trials (appendix). All patients 
were actively mobilised by the critical care physiotherapy 
team from admission using a step-wise programme 
according to daily clinical status, from passively moving 
the patient’s limbs to walking with assistance. ICU 
patients with RASS scores of –2 and upward were 
routinely sat out of bed unless there was a contraindication.
If patients developed acute agitation (RASS +2 and 
above) while on study drug, they were assessed for 
reversible causes, which were treated. Identiﬁ cation and 
management of reversible causes of agitation were left to 
the bedside nurse and doctor responsible for the patient’s 
clinical care and not recorded in trial data. If the patient’s 
agitation did not resolve, the patient was given up to 
10 mg of intravenous haloperidol in a 24 h period, in 
separate doses of 2·5–5·0 mg. The frequency and dose of 
any other antipsychotics given was also recorded.
All study patients had continuous electrocardiogram 
(ECG) monitoring plus a daily 12-lead ECG. If the QTc 
increased to more than 500 ms, study drug administration 
was temporarily withheld while any reversible causes, 
including hypokalaemia or hypomagnesaemia, were 
corrected. Once the QTc was less than 500 ms, study 
drug was restarted at half dose. If serum potassium and 
magnesium were normal or the study drug was already 
at half dose, the drug was stopped.
Patients were monitored for extrapyramidal symptoms 
daily using a modiﬁ ed Simpson-Angus scale.21 If a patient 
developed extrapyramidal symptoms the study drug dose 
was halved. If the symptoms continued after 24 h despite 
dose reduction the study drug was stopped. Adverse 
events were assessed for possible relation to study drug 
for up to 30 days after enrolment.
Demographic characteristics were recorded at the time 
of enrolment. Data were recorded daily while the patient 





Age at randomisation (years) 67·9 (16·5) 68·7 (14·9)
Men 37 (52%) 45 (64%)
Time from ICU admission to randomisation 
(days)
0·9 (0·91) 0·88 (0·81)
Main diagnosis at ICU admission* 
Sepsis or ARDS 25 (35%) 27 (39%) 
Pneumonia 20 (28%) 20 (29%)
Acute coronary syndrome or cardiac failure 5 (7%) 6 (9%)
Renal or hepatic failure 3 (4%) 3 (4%)
Haemorrhage 6 (8%) 4 (6%)
COPD 1 (1%) 2 (3%)
Drug overdose 2 (3%) 0
Other 10 (14%) 8 (11%)
Medical patient 42 (59%) 49 (70%)
Surgical patient 29 (41%) 21 (30%)
APACHE II score (points) 19·8 (6·2) 19·7 (6·9)
Data are mean (SD) or n (%). ICU=intensive-care unit. ARDS=acute respiratory 
distress syndrome. COPD=chronic obstructive pulmonary disease. APACHE=acute 
physiology and chronic health evaluation. *One patient in the haloperidol group 
had two main diagnoses. 





2 days CAM-ICU negative 20 (28%) 26 (37%)
Discharge from ICU 17 (24%) 12 (17%)
Oversedation 8 (11%) 5 (7%)
QTc 500 ms or over 7 (10%) 4 (6%)
Died 5 (7%) 4 (6%)
Discontinuation of active treatment 3 (4%) 7 (10%)
14 days after randomisation 3 (4%) 6 (9%)
Extrapyramidal symptoms 0 1 (1%)
Other 8 (11%) 5 (7%)
Data are number (%). CAM-ICU=confusion assessment method for the 
intensive-care unit.
Table 2: Reasons for study drug termination
See Online for appendix
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The primary outcome was delirium-free and coma-free 
days, deﬁ ned as the number of days in the ﬁ rst 14 days 
after randomisation during which the patient was alive 
without delirium and not in coma from any cause. 
Patients who died within the 14 day study period were 
recorded as having 0 days free of delirium and coma. 
This outcome measure best identiﬁ es improvement in 
the duration of normal cognitive status—ie, when the 
patient is alert and devoid of delirium.
Secondary outcomes were delirium-free and coma-free 
days to day 28, ventilator-free days from randomisation to 
day 28, mortality at 28 days, length of critical care and 
hospital stay, and safety with regard to prolonged QTc, 
extrapyramidal eﬀ ects, and serious adverse events 
attributed to study drug. We deﬁ ned ventilator-free days 
as the number of calendar days after a patient started 
unassisted breathing, for patients who survived at least 
48 consecutive hours after the start of unassisted 
breathing.22 Patients who died within 28 days of 
randomisation were counted as having no delirium-free 
and coma-free days or ventilator-free days.
Patients were deﬁ ned as delirious if they were assessed 
with a RASS of –2 to +4, and screened positive for 
delirium by the bedside nurse using the CAM-ICU. 
Patients with a RASS score of –3 to –5 were classiﬁ ed as 
in a coma, irrespective of whether the state was induced 
by disease or sedation. Delirium was assessed using the 
CAM-ICU twice during each 12 h shift with a minimum 
of 4 h between the two assessment points. All assessments 
in a 24 h period needed to be negative for a patient to be 
delirium-free and coma-free. If any assessment was 
CAM-ICU positive in a midnight to midnight 24 h 
period, that day was recorded as “with delirium”.
The study prespeciﬁ ed confounders were age, sex, and 
acute physiology and chronic health evaluation 
(APACHE) score.
Statistical analysis
Because the primary outcome has a non-normal 
distribution, we planned to use a non-parametric test for 
analysis. The power-eﬃ  ciency of the Wilcoxon rank sum 
test is expected to be about 95% compared with a t test, 
and therefore the sample size needed for a Wilcoxon test 
would be 1·053 times as many as needed for a t test. To 
achieve a statistically signiﬁ cant result (p<0·05) with 
80% power and a true treatment diﬀ erence of 2 days 
(SD 0·5), 64 participants were needed per group. After 
increasing the number of recruits by 1·053 times and 
allowing for 5% loss to follow-up, the target sample size 
was 71 per group (142 total).
Analyses were done according to the intention-to-treat 
principle, all randomised participants were included, and 
were analysed in their randomised groups irrespective of 
treatment actually received. We compared dichotomous 
outcomes using risk ratios and 95% CIs. For the primary 
outcome and other outcomes expected to have 
substantially non-normal distributions, non-parametric 
tests comparing ranking of individual outcomes were 
used to calculate p values. To inform the size of diﬀ erence 
and uncertainty we calculated the diﬀ erence in means 
between the groups, and used bootstrapping to estimate 
95% CIs. For other continuous outcomes, we used t tests 
and standard methods of calculating CIs. We checked 
normality of data using Shapiro-Wilk tests and Q-Q plots 
in SPSS. We used SAS (version 9.3) and SPSS (version 21) 





Diﬀ erence (95% CI)* 
or RR (95% CI)*
p value
Alive, delirium-free, and coma-free 
days in ﬁ rst 14 days
5 (0–10) 6 (0–11) –0·48 (–2·08 to 1·21) 0·53
Days in delirium in ﬁ rst 14 days† 5 (2–8) 5 (1–8) 0·01 (–1·31 to 1·33) 0·99
Days in coma in ﬁ rst 14 days† 0 (0–2) 0·5 (0–2) 0·00 (–0·68 to 0·67) 0·99
Alive, delirium–free, and coma-free 
days in ﬁ rst 28 days
19 (0–24) 19·5 (0–25) –0·26 (–3·72 to 3·46) 0·57
Days in delirium in ﬁ rst 28 days† 5 (2–10) 5 (1–9) –0·38 (–2·37 to 1·62) 0·71
Days in coma in ﬁ rst 28 days† 0 (0–2) 1 (0–2) –0·05 (–0·82 to 0·72) 0·90
Ventilator-free days in ﬁ rst 28 days 21 (0–25) 17 (0–25) 0·25 (–3·26 to 4·16) 0·88
Mortality at 28 days 20 (28·2%) 19 (27·1%) RR 1·04 (0·61 to 1·77) ··
Length of critical care stay (days)‡ 9·5 (5–14) 9 (5–18) –1·45 (–5·42 to 2·52) 0·47
Length of hospital stay (days)§ 18·5 (12–31) 26 (15–40) –5·13 (–21·75 to 11·48) 0·54
Data are number (%), median (IQR), unless otherwise speciﬁ ed. RR=risk ratio. *CI bootstrapped. †Including patients 
who died within study period. ‡Excluding patients who died in ICU: n=52 for haloperidol, n=51 for placebo. §Excluding 
patients who died in hospital: n=42 for haloperidol, n=47 for placebo. 
Table 3: Outcomes
Figure 2: Proportion of study patients with resolution of delirium over time
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Standard Randomised Controlled Trial Registry, number 
ISRCTN83567338.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. VJP, SG, and DFM had access to 
the raw data. The corresponding author (VJP) had full 
access to all data and ﬁ nal responsibility for the decision 
to submit for publication.
Results
Between Nov 9, 2010, and Sept 21, 2012, 677 patients were 
screened and 142 patients were enrolled; 71 patients were 
allocated to placebo and 71 to haloperidol (ﬁ gure 1). One 
patient in the placebo group was withdrawn after failure 
to obtain consent to continue or use collected data, this 
patient’s data were not included in the ﬁ nal analysis.
The two groups were much the same at baseline with 
regard to demographics, severity of illness, and ICU 
admission diagnoses (table 1). The mean number of 
doses of study drug per patient was 15·8 (SD 10·8) in the 
haloperidol group and 16·8 (11·2) in the placebo group. 
The reason study drug was discontinued in most patients 
was either because they screened negative for delirium 
on 2 consecutive days or were discharged from the ICU 
(table 2).
During the 14 day period from randomisation, patients 
in the haloperidol group spent about the same number 
of days alive without delirium and without coma as did 
patients in the placebo group (median 5 days [IQR 0–10] 
in the haloperidol group vs 6 days in the placebo group 
[0–11]; p=0·53; table 3). The number of days assessed as 
spent in delirium (as opposed to coma or normal) did not 
diﬀ er between the two groups (median 5 days [IQR 2–8] 
in the haloperidol group vs 5 days [1–8] in the placebo 
group; p=0·99). Figure 2 shows the daily rate of recovery 
from delirium and coma in both groups as the proportion 
of study patients alive, delirium-free, and coma-free. Ten 
patients restarted study drug because of new delirium 
within 14 days, seven in the haloperidol group and three 
in the placebo group. We identiﬁ ed no diﬀ erences in 
secondary outcomes, including ventilator-free days, 
length of critical care stay, length of hospital stay, and 
mortality at 28 days (table 3).
In addition to the study drug, 18 patients in the 
placebo group and eight patients in the haloperidol 
group received additional open-label antipsychotic 
medication, most often haloperidol. Most patients 
received one or two doses of antipsychotic treatment. 
The risk of needing additional antipsychotic treatment 
was signiﬁ cantly lower in patients receiving haloperidol 
than in those in the placebo group (table 4). Patients in 
the placebo group received haloperidol for an average 
of 0·41 days (SD 1·0). Although there was no statistical 
diﬀ erence between use of individual sedative or 
opioid drugs between groups, our results suggest that 
haloperidol might reduce the need for sedatives 
(table 5).
A secondary data analysis showed that a lower 
proportion of patients had a RASS of +2 or more in the 
haloperidol group than in the placebo group (median 
13% [IQR 8·75–17·00] vs 20% [17·50– 26·75]; p=0·0075; 
ﬁ gure 3).
The most common adverse event was oversedation (11 
[15%] in haloperidol group vs six [9%] in placebo group; 
table 6). No serious adverse events were attributable to the 
study drug (table 6). QTc prolongation of 500 ms or more 
occurred in seven patients receiving haloperidol compared 
with six patients in the placebo group. Two patients in the 
placebo group had halving of the study drug because of QT 
prolongation, which responded to correction of plasma 
electrolytes. Eleven of the patients had the study drug 
stopped, of whom two patients in the haloperidol group 
Haloperidol (n=71) Placebo (n=70) Diﬀ erence (95% CI*) p value
Fentanyl
Patients treated 62 (87%) 58 (83%) ··
Total dose (mg) 8·62 (10·93) 14·24 (22·29) –5·62 (–11·46 to 0·21) 0·06
Number of days 4·48 (3·40–5·56) 5·50 (4·11–6·89) –1·02 (–2·76 to 0·72) 0·25
Propofol
Patients treated 57 (80%) 63 (90%) ··
Total dose (mg) 5308 (7663) 8170 (10 343) –2862 (–5890 to 166) 0·06
Number of days 3·89 (4·35) 5·19 (4·38) –1·30 (–2·75 to 0·16) 0·08
Clonidine
Patients treated 5 (7%) 2 (3%) ··
Total dose (mg) 0·71 (4·69) 0·18 (1·12) 0·53 (–0·61 to 1·67) 0·36
Number of days 0·20 (0·82) 0·14 (0·86) 0·05 (–0·23 to 0·33) 0·70
Midazolam
Patients treated 15 (21%) 16 (23%) ··
Total dose (mg) 8·37 (28·92) 48·74 (195·02) –40·38 (–86·6 to 5·89) 0·09
Number of days 0·35 (0·81) 0·76 (2·16) –0·41 (–0·95 to 0·14) 0·14
Morphine
Patients treated 13 (18%) 16 (23%) ··
Total dose (mg) 12·57 (52·65) 25·94 (77·49) –13·37 (–35·40 to 8·66) 0·23
Number of days 0·56 (1·59) 0·50 (1·10) 0·06 (–0·39 to 0·52) 0·78
Data are n (%) or mean (SD) unless otherwise speciﬁ ed. *CI bootstrapped.





Diﬀ erence (95% CI) or 
RR (95% CI)
p value
Any antipsychotic* 8 (11%) 18 (26%) RR 0·44 (0·20 to 0·94) ··
Open-label haloperidol
Patients treated 6 (8%) 15 (21%) RR 0·39 (0·16 to 0·96) ··
Number of days 0·17 (0·59) 0·41 (1·00) Diﬀ erence –0·25 (–0·52 to 0·03) 0·08
Total dose (mg) 1·0 (4·05) 1·71 (4·41) Diﬀ erence –0·71 (–2·12 to 0·70) 0·32
Data are n (%) or mean (SD) unless otherwise speciﬁ ed. RR=risk ratio. *In the haloperidol group, one patient received 
olanzapine and one patient received additional haloperidol and olanzapine. In the placebo group, two patients 
received haloperidol, olanzapine, and quetiapine, and one patient received haloperidol and olanzapine. 
Table 4: Use of other antipsychotics
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had been already on half dose study drug when QTc over 
500 ms, one for over sedation and one for excessive 
salivation. None of these patients had ventricular 
arrhythmias and speciﬁ cally no patient had an episode of 
torsades de pointes. Extrapyramidal symptoms suﬃ  cient 
to stop the study drug occurred in only one patient, who 
was receiving placebo. Study drug was stopped in eight 
patients in the haloperidol group and ﬁ ve patients in the 
placebo group because of oversedation in patients who 
were no longer on sedative or analgesic infusions (table 2). 
Three patients were thought to have akathisia, only one of 
whom was on haloperidol, the study drug was halved, and 
in one patient who was not on haloperidol, the drug was 
already at half dose so the drug was stopped.
Discussion
In this study, early treatment with haloperidol did not 
modify the prevalence or duration of delirium or coma in 
critically ill patients needing mechanical ventilation. The 
average duration of delirium in these patients was about 
5 days in both groups. Furthermore, haloperidol did not 
have an eﬀ ect on any secondary clinical outcomes.
Only four placebo-controlled eﬃ  cacy trials of 
antipsychotics in critical care patients have been reported, 
all with limitations either in type or number of patients or 
study design (panel).23–31 Studies in critically ill patients 
using haloperidol are limited in quality, such that the 
recent pain, agitation, and delirium clinical practice 
guidelines from the American College of Critical Care 
Medicine concluded that no recommendation could be 
made regarding the use of haloperidol to prevent or treat 
delirium in adult ICU patients.30 One trial28 in 457 post-
operative, mainly elective, patients admitted to ICUs in 
Beijing did show a reduction in the incidence of delirium 
using prophylactic, low dose haloperidol (0·5 mg bolus 
injection followed by an infusion of 0·1 mg/h for 12 h) 
compared with placebo. The study population was not 
critically ill, with a mean APACHE score of less than nine 
and a median ICU stay of less than 24 h. Only 35 patients 
(15·3%) in the haloperidol group and 53 patients (23·2%) 
in the placebo group developed delirium. A smaller pilot 
study29 done in the USA did not show a reduction in ICU 
delirium using enteral haloperidol or ziprasidone, but was 
designed to assess feasibility, not powered for clinical 
outcomes. A before-and-after study seemed to show that 
low dose haloperidol prophylaxis in higher risk critically ill 
patients might have beneﬁ cial eﬀ ects, although this study 
design had limitations.14
Although our study was not powered to show a diﬀ erence 
between the use of individual psychotropic or opioid drugs 
between groups, our results suggest that haloperidol might 
reduce the need for sedatives. Propofol is mainly 
metabolised by cytochrome P450, isoform CYP2B6, and it 
has been shown in vitro to inhibit CYP3A4, an isoform 
involved in the biotransformation of haloperidol in human 
beings.32,33 Data suggest the degree of inhibition of CYP3A4 
by propofol would be unlikely to have any pronounced 
clinical signiﬁ cance.34 This was not a mechanistic study and 
the pharmacokinetic and genetic factors aﬀ ecting 
individual patient CYP activity and diﬀ erent drugs are 
complex. Since there was no diﬀ erence in delirium or 
coma with the use of haloperidol it is unlikely any 
pharmacokinetic interaction had any signiﬁ cant eﬀ ect on 
the primary outcome. The decreased exposure to sedative 
drugs in the haloperidol group did not translate into more 
delirium-free, coma-free days, which is consistent with the 



























3 4 5 6 7 8 9 10 11 12 13 14
Haloperidol Placebo
All
Oversedation 11 (15%) 6 (9%)
Decreased consciousness* 2 (3%) 1 (1%)
Self-extubation 1 (1%) 2 (3%)
QTc prolongation >500 ms 7 (10%) 6 (9%)
Sinus tachycardia 0 1 (1%)
Atrial ﬁ brillation 7 (10%) 3 (4%)
Supraventricular tachycardia 4 (6%) 1 (1%)
Ventricular ectopics 0 1 (1%)
Bradycardia 2 (3%) 0
Non-speciﬁ c ECG changes 0 2 (3%)
Hypotension 3 (4%) 2 (3%)
Desaturation 1 (1%) 1 (1%)
Akathisia 1 (1%) 2 (3%)
Excessive salivation 2 (3%) 0
Muscle stiﬀ ness 1 (1%) 1 (3%)
Torticollis 0 1 (3%)
Blurred vision 1 (3%) 0
Serious
Apnoea post treatment for agitation 0 1 (3%)
Fast atrial ﬁ brillation with hypotension 1 (3%) 0
Readmission to ICU with sepsis 1 (3%) 1 (1%)
Failed extubation 1 (3%) 3 (4%)
Data are n (%). 13 participants had more than one event.  *Not sedation-related. 
Table 6: Adverse events
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results of a study35 comparing biological and drug treatment 
characteristics in 99 ICU patients with coma or delirium, or 
both, which showed that unlike coma, delirium was 
unrelated to sedative exposure. Agitation remains the most 
common motivation for use of haloperidol in critically ill 
patients and a lower proportion of patients had a RASS of 
+2 or more in the group who received haloperidol compared 
with those who received placebo. Thus, haloperidol is a 
useful agent for management of agitation despite having 
no eﬀ ect on delirium.
The strengths of this study include the study design as 
a randomised, double-blind, placebo-controlled trial. 
Patients were started on the study drug early irrespective 
of whether they had screened positive for delirium or 
were in coma. The power calculations on which this 
study is based support that the number of patients 
included would show a diﬀ erence of alive, delirium-free, 
coma-free days if any existed. As a randomised controlled 
trial any confounding variables would be expected to be 
present equally between the two groups, and there was 
no indication of imbalance in baseline variables 
measured. The low median number of days patients 
spent in coma in the ﬁ rst 14 days (0 days [IQR 0–2] in the 
haloperidol group vs 0·5 days [0–2] in the placebo group) 
suggests that patients were managed in keeping with a 
RASS range of 0 to –2, ie, not deep sedation.36
The study has several limitations. This was a single site 
study, although the population of patients was broadly 
representative of the general ICU population in the UK 
and internationally. As with most critical care research, 
the patients’ admission diagnoses were wide ranging and 
the number of surgical patients and those with an 
admission diagnosis of sepsis were much the same in 
both groups. There might have been an imbalance of risk 
factors for which data were not collected; however, we 
would not expect such an imbalance in a randomised 
trial. It might be that a subset of critically ill patients (eg, 
those with established delirium) would beneﬁ t from 
routine haloperidol, although in view of the results of 
this study the beneﬁ t would probably be small, and a 
much larger study would be needed to show it.
Deﬁ ning normal cognitive function as the absence of 
delirium and coma in a patient is an inevitable constraint 
because it is not possible to be conﬁ dent in delineating 
the cause of coma as disorder or drugs in many ICU 
patients. Hence we used a clinical diagnosis based on the 
absence of symptoms, using a valid instrument but 
without attempting to claim causality, then collected 
observations as to the persistence or not of symptoms. An 
intervention to reduce days with delirium could achieve 
its goal not by increasing days without delirium, but by 
increasing days with coma. We used the combination of 
delirium-free and coma-free to ensure that a reduction in 
delirium was indicative of a patient’s brain recovering 
towards a normal state, rather than moving into coma.
Patients who died within 14 days were assessed with 
zero delirium-free, coma-free days to manage the possible 
conﬂ icting eﬀ ects of haloperidol on delirium and survival 
in the same way that days alive and free from mechanical 
ventilation are used as an outcome measure in treatments 
for adult respiratory distress syndrome.22 If haloperidol 
was associated with increased mortality in the ﬁ rst 14 days, 
then haloperidol might be reported to improve delirium, 
even though this eﬀ ect might be attributable to patients 
dying earlier, which is clearly not beneﬁ cial. The number 
of days in delirium and days in coma in all patients are 
presented in table 3, which when considered with the 
secondary outcome of mortality, show the groups do not 
diﬀ er. Thus in patients who died of an unrelated cause, 
haloperidol did not modulate delirium.
Although we cannot conﬁ dently exclude an eﬀ ect with 
a much higher dose of haloperidol, PET scan studies 
show that doses of 2–5 mg per day, giving plasma 
concentrations of 1–2 ng/mL, induce 60–80% dopamine 
D2 receptor occupancy; 70% is deemed adequate for 
typical neuroleptic response.37 Furthermore Medsafe, the 
New Zealand medicines safety authority, have reviewed 
available data and recommend that doses greater than 
10 mg per day are unlikely to provide further eﬃ  cacy, but 
might lead to increased adverse eﬀ ects.38
The dose of haloperidol might be considered large 
outside of the critical care setting. The British Geriatric 
Society guidelines recommend 0·5 mg orally up to every 
2 h. In patients taking oral haloperidol 2 mg daily, mean 
plasma haloperidol concentrations were about twice as 
Panel: Research in context
Systematic review
We searched PubMed with the key words “intensive care”, “critical care”, “delirium”, and 
“antipsychotics”, for studies reported in English up to April 18, 2013. We included only studies 
in adult patients. There are three relevant Cochrane reviews.23–25 They concluded that although 
low dose haloperidol might be eﬀ ective in postoperative patients, there was a scarcity of 
robust information on delirium prevention and that in terminally ill patients there was little 
evidence for the role of drug therapy in management of delirium. Four placebo-controlled 
randomised trials26–29 have been done in intensive-care unit (ICU) patients, with variable 
results, from small eﬀ ects to no beneﬁ t. However, two of these trials were small. There are 
some reports of harm with the use of antipsychotics in elderly patients.
Clinical practice guidelines30 for the sustained use of sedatives and analgesics in the critically ill 
adult were reported in January, 2013, based on a review of evidence identiﬁ ed from a systematic 
review, guided by key words provided by four subcommittees of experts. With regard to 
delirium the subcommittee identiﬁ ed no double-blind, randomised, placebo-controlled 
trials of adequate power to establish the eﬃ  cacy or safety of any antipsychotic agent in the 
management of delirium in ICU patients. They also concluded that robust data for haloperidol 
in non-ICU patients, which could potentially be applied to the ICU setting, are absent.
Interpretation
As far as we are aware, our study is the ﬁ rst double-blind, randomised, controlled eﬃ  cacy trial 
designed and powered to establish whether haloperidol will modify delirium in critically ill 
patients. We identiﬁ ed no diﬀ erence between the haloperidol and placebo groups. This 
ﬁ nding supports UK National Institution of Clinical Excellence guidelines,31 based on expert 
opinion, that antipsychotics should only be used when non-pharmacological methods have 
not worked and a patient is distressed or a danger to themselves or others.
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high in elderly patients compared with adult patients 
with schizophrenia.39 However, a US survey of 250 critical 
care pharmacists from eight states conﬁ rmed that more 
than 50% use a scheduled daily dose of 5–10 mg 
intravenously, in keeping with this study dose which was 
informed by the UK Intensive Care Foundation survey of 
current practice.7,40
Our group of patients had a high prevalence of coma 
(deep sedation) or delirium in the ﬁ rst 48 h. Our previous 
data suggested that at least 65% would have delirium.8 
However, since we included patients who were assessed as 
RASS –3 in the present study, we expected the prevalence 
to be higher. This expectation was in keeping with data 
from the Australian and New Zealand Intensive Care 
Society (ANZICS), which showed that more than 75% of 
patients had a RASS of –3 or worse early in the course of 
ICU stay.36 The low numbers of patients assessed as free of 
delirium and coma could also be due to the frequency and 
timing of RASS and CAM-ICU assessments; study 
patients were assessed four times daily and only needed to 
have one assessment of RASS –3 or less, or screen positive 
once for delirium for that day, to count as not delirium-free 
or coma-free. Additionally, according to the ANZICS data, 
patients were more likely to be assessed as not being 
delirium or coma free when an assessment was done soon 
after the patient was sedated and ventilated.
The use of open label antipsychotics when clinically 
indicated meant that some placebo patients received 
antipsychotics and therefore were not truly receiving 
placebo alone. However, the amounts used were minimal 
and there was no diﬀ erence between the overall doses of 
open label haloperidol used (mean 1·0 mg [SD 4·05] in 
haloperidol group vs 1·71 mg [4·41] in the placebo group). 
Currently, the belief in the eﬃ  cacy of haloperidol in 
delirium is such that it was not possible to obtain ethical 
approval to undertake a placebo-controlled trial without 
allowing the option of rescue haloperidol. 
Abruptly stopping haloperidol after a patient screened 
negative for 2 days might have resulted in the loss of a 
sustained preventive eﬀ ect. Since intravenous haloperidol 
is not generally used outside of critical care and being 
delirium free would suggest clinical improvement such 
that discharge from critical care would be anticipated, we 
believed that stopping the study drug after 2 days would 
be most practically and clinically relevant. In fact, ten 
patients needed to restart the study drug for new delirium, 
seven patients receiving haloperidol and three receiving 
placebo. The assumption that once a patient had been 
discharged from the ICU, they were free of delirium is 
also a limitation of this study. We used the CAM-ICU as a 
relevant instrument to detect delirium in this ICU study 
population. It has been endorsed by the American College 
of Critical Care Medicine as a valid and reliable non-verbal 
instrument and this notion has been conﬁ rmed by a meta-
analysis.30,41 However, the CAM-ICU has not been shown 
to be a valid delirium-screening instrument outside of the 
critical care environment.42 Episodes of delirium would be 
expected to negatively aﬀ ect clinical progress of patients 
once discharged from the ICU, potentially leading to 
longer hospital stays.43 However, since length of hospital 
stay did not diﬀ er between the two groups, it is unlikely 
that undocumented episodes of delirium after ICU 
discharge, within the 14 day study period, would change 
the result of the primary outcome.
Despite a limited evidence base, increasing numbers of 
patients are being exposed to haloperidol for the 
management of delirium. Our results suggest a commonly 
used haloperidol dose regimen does not decrease delirium 
in an unselected population of critically ill patients 
requiring mechanical ventilation, when commenced early 
during ICU stay. Identiﬁ cation of a pharmacological 
intervention to prevent or reduce delirium and improve 
adverse outcomes, including in the ICU setting, remains 
a high priority within delirium research.28
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